Merck acquires EyeBio

Fact checked byHeather Biele

Merck has announced the acquisition of all outstanding shares of EyeBio, making it a wholly-owned subsidiary, according to a company press release.

“The EyeBio acquisition further diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases,” Dean Y. Li, MD, PhD, president of Merck Research Laboratories, said in the release. “We are excited to welcome the EyeBio team and look forward to working together to advance Restoret for the patients that need it.”

Corporate looking handshake_Adobe — The acquisition of EyeBio expands Merck’s drug pipeline to include Restoret, a novel candidate for diabetic macular edema and neovascular age-related macular degeneration. *Image: Adobe Stock*

According to the release, Restoret is EyeBio’s investigational, tri-specific antibody designed to treat vascular leakage in retinal diseases. It is administered via intravitreal injection. Positive results from the open-label phase 1b/2a AMARONE study of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration are expected to advance Restoret into a phase 2b/3 trial for DME later this year.

Along with Restoret, Merck also will acquire other clinical and preclinical pipeline candidates under development for prevention and treatment of vision loss linked to retinal vascular leakage, the release stated.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Merck acquires EyeBio

Related Content